Chandravadan R Shah

This inventor holds 36 USPTO granted patents and 7 published patent applications, plus 3 CIPO patents and 8 EPO patents, primarily in Heterocyclic Compounds. Top assignees: Janssen Pharmaceutica Nv, Ortho-Mcneil Pharmaceutical Corp., Epigen Biosciences, Inc.. Active years: 2004-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Chandravadan R Shah. Retrieved from https://idiyas.com/inventor/chandravadan-r-shah

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 36 (Patent Applications = 7)

% Patents Active = 91.7

CIPO Patents = 3 (Patent Applications = 3)

EPO Patents = 8 (Patent Applications = 8)

Average Co-Inventor Count = 5.8

ph-index = 7

Forward Citations = 103(Granted Patents)

Company Filing History:

19 out of 2,101

Janssen Pharmaceutica Nv

patents

8 out of 363

Ortho-Mcneil Pharmaceutical Corp.

patents

6 out of 6

Epigen Biosciences, Inc.

patents

4. 1 out of 32

Janssen Pharmaceutica

patents

5. 2 out of 834,570

Other

patents

Years Active: 2004-2025

Loading Chart...

Areas of Expertise:

Heterocyclic Compounds

Orexin Receptor Modulators

Serotonin Receptor Modulators

Pyrimidine Compounds

Pyridine Amine Compounds

Piperazines

Piperidines

Naphthyridine Compounds

Phenylpiperidines

Phenylpyrrolidines

Non-Imidazole Compounds

36 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12378254 - Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators (2025-08-05),

2. 12234224 - Pyrimidine and pyridine amine compounds and usage thereof in disease treatment (2025-02-25),

3. 11866421 - Pyrimidine and pyridine amine compounds and usage thereof in disease treatment (2024-01-09),

4. 11667644 - Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators (2023-06-06),

5. 11427552 - Heterocyclic compounds useful in the treatment of disease (2022-08-30),

6. RE48841 - Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators (2021-12-06),

7. 11059828 - Disubstituted octahydropyrrolo[3,4-C]pyrroles as orexin receptor modulators (2021-07-13),

8. 10570103 - Heterocyclic compounds useful in the treatment of disease (2020-02-25),

9. 10526298 - Heterocyclic compounds useful in the treatment of disease (2020-01-07),

10. 10000459 - Heterocyclic compounds useful in the treatment of disease (2018-06-19),

11. 9981909 - Serotonin receptor modulators (2018-05-29),

12. 9079911 - Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators (2015-07-14),

13. 9062044 - Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators (2015-06-23),

14. 8680275 - Fused heterocyclic compounds as orexin receptor modulators (2014-03-25),

15. 8653263 - Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators (2014-02-18),

Title: Chandravadan R Shah - Pioneering Inventor from San Diego

Introduction: Chandravadan R Shah is a renowned inventor based in San Diego, California, known for his groundbreaking contributions to the field of technology and innovation.

Latest Patents: Chandravadan R Shah holds several patents in various technological domains, including artificial intelligence, renewable energy, and medical devices.

Career Highlights: With a career spanning over three decades, Chandravadan R Shah has worked with leading tech companies, research institutions, and universities to develop cutting-edge solutions that have revolutionized industries.

Collaborations: Throughout his career, Chandravadan R Shah has collaborated with top scientists, engineers, and researchers to bring his innovative ideas to life. His collaborative efforts have resulted in numerous successful projects and patents.

Conclusion: Chandravadan R Shah's passion for innovation and his relentless pursuit of excellence have solidified his reputation as a visionary inventor in the tech world. His contributions continue to inspire the next generation of inventors and shape the future of technology.

Profile summary based on public USPTO records.